Trial
NCT06865677
Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
National Cancer Institute (NCI)
Collaborators
—
Condition
Recurrent Platinum Resistant Epithelial Ovarian Carcinoma
Intervention
Sacituzumab Govitecan
Why stopped
This protocol was terminated prematurely because the prior principal investigator departed the Institute without treating any participants.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-01-21